Fresh Noncultured Endothelial Progenitor Cells Improve Neonatal Lung Hyperoxia-Induced Alveolar Injury

Alexandra B. Firsova, A. Daniel Bird, Degu Abebe, Judy Ng, Richard Mollard, Timothy J. Cole

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Treatment of preterm human infants with high oxygen can result in disrupted lung alveolar and vascular development. Local or systemic administration of endothelial progenitor cells (EPCs) is reported to remedy such disruption in animal models. In this study, the effects of both fresh (enriched for KDR) and cultured bone marrow (BM)-derived cell populations with EPC characteristics were examined following hyperoxia in neonatal mouse lungs. Intraperitoneal injection of fresh EPCs into five-day-old mice treated with 90% oxygen resulted in full recovery of hyperoxia-induced alveolar disruption by 56 days of age. Partial recovery in septal number following hyperoxia was observed following injection of short-term cultured EPCs, yet aberrant tissue growths appeared following injection of long-term cultured cells. Fresh and long-term cultured cells had no impact on blood vessel development. Short-term cultured cells increased blood vessel number in normoxic and hyperoxic mice by 28 days but had no impact on day 56. Injection of fresh EPCs into normoxic mice significantly reduced alveolarization compared with phosphate buffered saline-injected normoxic controls. These results indicate that fresh BM EPCs have a higher and safer corrective profile in a hyperoxia-induced lung injury model compared with cultured BM EPCs but may be detrimental to the normoxic lung. The appearance of aberrant tissue growths and other side effects following injection of cultured EPCs warrants further investigation. Stem Cells Translational Medicine 2017;6:2094–2105.

Original languageEnglish
Pages (from-to)2094-2105
Number of pages12
JournalStem Cells Translational Medicine
Volume6
Issue number12
DOIs
Publication statusPublished - 1 Dec 2017

Keywords

  • Alveolarization
  • Bone marrow
  • Cell therapy
  • Cultured cells
  • Endothelial progenitor cells
  • Fresh cells
  • Hyperoxia
  • Lung injury
  • Side effects

Cite this

@article{ceb5a24635f84b20b724849e09f85a5b,
title = "Fresh Noncultured Endothelial Progenitor Cells Improve Neonatal Lung Hyperoxia-Induced Alveolar Injury",
abstract = "Treatment of preterm human infants with high oxygen can result in disrupted lung alveolar and vascular development. Local or systemic administration of endothelial progenitor cells (EPCs) is reported to remedy such disruption in animal models. In this study, the effects of both fresh (enriched for KDR) and cultured bone marrow (BM)-derived cell populations with EPC characteristics were examined following hyperoxia in neonatal mouse lungs. Intraperitoneal injection of fresh EPCs into five-day-old mice treated with 90{\%} oxygen resulted in full recovery of hyperoxia-induced alveolar disruption by 56 days of age. Partial recovery in septal number following hyperoxia was observed following injection of short-term cultured EPCs, yet aberrant tissue growths appeared following injection of long-term cultured cells. Fresh and long-term cultured cells had no impact on blood vessel development. Short-term cultured cells increased blood vessel number in normoxic and hyperoxic mice by 28 days but had no impact on day 56. Injection of fresh EPCs into normoxic mice significantly reduced alveolarization compared with phosphate buffered saline-injected normoxic controls. These results indicate that fresh BM EPCs have a higher and safer corrective profile in a hyperoxia-induced lung injury model compared with cultured BM EPCs but may be detrimental to the normoxic lung. The appearance of aberrant tissue growths and other side effects following injection of cultured EPCs warrants further investigation. Stem Cells Translational Medicine 2017;6:2094–2105.",
keywords = "Alveolarization, Bone marrow, Cell therapy, Cultured cells, Endothelial progenitor cells, Fresh cells, Hyperoxia, Lung injury, Side effects",
author = "Firsova, {Alexandra B.} and Bird, {A. Daniel} and Degu Abebe and Judy Ng and Richard Mollard and Cole, {Timothy J.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/sctm.17-0093",
language = "English",
volume = "6",
pages = "2094--2105",
journal = "Stem Cells Translational Medicine",
issn = "2157-6564",
publisher = "Alphamed Press",
number = "12",

}

Fresh Noncultured Endothelial Progenitor Cells Improve Neonatal Lung Hyperoxia-Induced Alveolar Injury. / Firsova, Alexandra B.; Bird, A. Daniel; Abebe, Degu; Ng, Judy; Mollard, Richard; Cole, Timothy J.

In: Stem Cells Translational Medicine, Vol. 6, No. 12, 01.12.2017, p. 2094-2105.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Fresh Noncultured Endothelial Progenitor Cells Improve Neonatal Lung Hyperoxia-Induced Alveolar Injury

AU - Firsova, Alexandra B.

AU - Bird, A. Daniel

AU - Abebe, Degu

AU - Ng, Judy

AU - Mollard, Richard

AU - Cole, Timothy J.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Treatment of preterm human infants with high oxygen can result in disrupted lung alveolar and vascular development. Local or systemic administration of endothelial progenitor cells (EPCs) is reported to remedy such disruption in animal models. In this study, the effects of both fresh (enriched for KDR) and cultured bone marrow (BM)-derived cell populations with EPC characteristics were examined following hyperoxia in neonatal mouse lungs. Intraperitoneal injection of fresh EPCs into five-day-old mice treated with 90% oxygen resulted in full recovery of hyperoxia-induced alveolar disruption by 56 days of age. Partial recovery in septal number following hyperoxia was observed following injection of short-term cultured EPCs, yet aberrant tissue growths appeared following injection of long-term cultured cells. Fresh and long-term cultured cells had no impact on blood vessel development. Short-term cultured cells increased blood vessel number in normoxic and hyperoxic mice by 28 days but had no impact on day 56. Injection of fresh EPCs into normoxic mice significantly reduced alveolarization compared with phosphate buffered saline-injected normoxic controls. These results indicate that fresh BM EPCs have a higher and safer corrective profile in a hyperoxia-induced lung injury model compared with cultured BM EPCs but may be detrimental to the normoxic lung. The appearance of aberrant tissue growths and other side effects following injection of cultured EPCs warrants further investigation. Stem Cells Translational Medicine 2017;6:2094–2105.

AB - Treatment of preterm human infants with high oxygen can result in disrupted lung alveolar and vascular development. Local or systemic administration of endothelial progenitor cells (EPCs) is reported to remedy such disruption in animal models. In this study, the effects of both fresh (enriched for KDR) and cultured bone marrow (BM)-derived cell populations with EPC characteristics were examined following hyperoxia in neonatal mouse lungs. Intraperitoneal injection of fresh EPCs into five-day-old mice treated with 90% oxygen resulted in full recovery of hyperoxia-induced alveolar disruption by 56 days of age. Partial recovery in septal number following hyperoxia was observed following injection of short-term cultured EPCs, yet aberrant tissue growths appeared following injection of long-term cultured cells. Fresh and long-term cultured cells had no impact on blood vessel development. Short-term cultured cells increased blood vessel number in normoxic and hyperoxic mice by 28 days but had no impact on day 56. Injection of fresh EPCs into normoxic mice significantly reduced alveolarization compared with phosphate buffered saline-injected normoxic controls. These results indicate that fresh BM EPCs have a higher and safer corrective profile in a hyperoxia-induced lung injury model compared with cultured BM EPCs but may be detrimental to the normoxic lung. The appearance of aberrant tissue growths and other side effects following injection of cultured EPCs warrants further investigation. Stem Cells Translational Medicine 2017;6:2094–2105.

KW - Alveolarization

KW - Bone marrow

KW - Cell therapy

KW - Cultured cells

KW - Endothelial progenitor cells

KW - Fresh cells

KW - Hyperoxia

KW - Lung injury

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=85031327230&partnerID=8YFLogxK

U2 - 10.1002/sctm.17-0093

DO - 10.1002/sctm.17-0093

M3 - Article

VL - 6

SP - 2094

EP - 2105

JO - Stem Cells Translational Medicine

JF - Stem Cells Translational Medicine

SN - 2157-6564

IS - 12

ER -